Posttransplant biliary complications in the pre‐ and post‐model for end‐stage liver disease era

Vinay Sundaram, Deborah T. Jones, Nilesh H. Shah, Michael E. de Vera, Paulo Fontes, J. Wallis Marsh, Abhinav Humar, Jawad Ahmad – 10 January 2011 – Biliary complications remain a cause of morbidity after liver transplantation. The aim of this study was to determine whether changes in clinical practice in the era of the Model for End‐Stage Liver Disease (MELD) has affected biliary complications after liver transplantation. We retrospectively reviewed all deceased donor liver transplants at a single center.

Comparative analysis of various tumor‐associated antigen‐specific t‐cell responses in patients with hepatocellular carcinoma

Eishiro Mizukoshi, Yasunari Nakamoto, Kuniaki Arai, Tatsuya Yamashita, Akito Sakai, Yoshio Sakai, Takashi Kagaya, Taro Yamashita, Masao Honda, Shuichi Kaneko – 10 January 2011 – Many tumor‐associated antigens (TAAs) recognized by cytotoxic T cells (CTLs) have been identified during the last two decades and some of them have been used in clinical trials. However, there are very few in the field of immunotherapy for hepatocellular carcinoma (HCC) because there have not been comparative data regarding CTL responses to various TAAs.

Host apolipoprotein b messenger RNA‐editing enzyme catalytic polypeptide‐like 3G is an innate defensive factor and drug target against hepatitis C virus

Zong‐Gen Peng, Zhi‐Yun Zhao, Yan‐Ping Li, Yu‐Ping Wang, Lan‐Hu Hao, Bo Fan, Yu‐Huan Li, Yue‐Ming Wang, Yong‐Qiang Shan, Yan‐Xing Han, Yan‐Ping Zhu, Jian‐Rui Li, Xue‐Fu You, Zhuo‐Rong Li, Jian‐Dong Jiang – 10 January 2011 – Host cellular factor apolipoprotein B messenger RNA (mRNA)‐editing enzyme catalytic polypeptide‐like 3G (hA3G) is a cytidine deaminase that inhibits a group of viruses including human immunodeficiency virus‐1 (HIV‐1). In the continuation of our research on hA3G, we found that hA3G stabilizing compounds significantly inhibited hepatitis C virus (HCV) replication.

Transcription factor Fra‐1 induces cholangitis and liver fibrosis

Trayana Kireva, Annette Erhardt, Gisa Tiegs, Herbert Tilg, Helmut Denk, Johannes Haybaeck, Elmar Aigner, Alexander Moschen, Jörg H. Distler, Georg Schett, Jochen Zwerina – 10 January 2011 – Chronic diseases of the biliary system are common and may cause fibrosis and eventually progression to liver cirrhosis. The aim was to define a new mouse model of a cholangiopathy leading to liver fibrosis in fra‐1tg mice. Liver pathology of fra‐1tg mice was analyzed in detail by histology and flow cytometry.

Virological response is associated with decline in hemoglobin concentration during pegylated interferon and ribavirin therapy in hepatitis C virus genotype 1

William Sievert, Gregory J. Dore, Geoffrey W. McCaughan, Motoko Yoshihara, Darrell H. Crawford, Wendy Cheng, Martin Weltman, William Rawlinson, Bishoy Rizkalla, Jean K. DePamphilis, Stuart K. Roberts, on behalf of the CHARIOT Study Group – 10 January 2011 – Anemia may increase the likelihood of achieving a sustained virological response (SVR) during pegylated interferon and ribavirin treatment of hepatitis C virus (HCV) infection. To determine whether hemoglobin decline is associated with SVR, we retrospectively evaluated the CHARIOT study of 871 treatment‐naïve HCV genotype 1 patients.

Is cytomegalovirus infection dangerous in cytomegalovirus‐seropositive recipients after liver transplantation?

Jong Man Kim, Sung‐Joo Kim, Jae‐Won Joh, Choon Hyuck David Kwon, Sanghyun Song, Milljae Shin, Ju Ik Moon, Gaab Soo Kim, Seung Heui Hong, Suk‐Koo Lee – 10 January 2011 – Cytomegalovirus (CMV) infections contracted after liver transplantation put patients at an increased risk of morbidity and mortality. We analyzed the effects of CMV infection by time of onset, mortality, and graft failure risk factors in liver recipients who were CMV donor‐positive/recipient‐positive (D+/R+). We reviewed 618 medical records for consecutive adult liver transplant cases.

Subscribe to